Author

OF Olopade

Observed name: O. Olopade

Institutions: University of Minnesota, Mayo Clinic, Buck Institute for Research on Aging, University of San Diego, University of California, San Francisco, Georgetown University, University of California San Diego, University of Chicago, University of Pennsylvania

Observed institutions: University of Minnesota, Mayo Clinic, Buck Institute for Research on Aging, University of San Diego, University of California, San Francisco, Georgetown University, University of California San Diego, University of Chicago, University of Pennsylvania

OpenAlex ID: A5047734394

532 Evaluation of a BRCAness signature as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 trial

2014 · A. Glas, J. Peeters, et al. · European Journal of Cancer · 9

Abstract P3-07-49: Residual cancer burden (RCB) with veliparib/carboplatin in the I-SPY2 trial

2016 · MC Liu, WF Symmans, et al. · Cancer Research · 1

Reliability of statistical tools to predict the likelihood of BRCA1 and BRCA2 gene mutations in individuals at high risk for breast and ovarian cancer

2011 · M HANKAMMER, OF Olopade, et al.

Works count: 3

Citation count: 10

H-index: 1

I10-index: